Business
CROSS-SPECTRUMBROAD COVERAGE
Moderna and Merck report positive topline results for personalized melanoma vaccine trial
Moderna and Merck said their experimental personalized mRNA vaccine, designed to encode up to 34 tumor neoantigens, produced positive topline results in an ongoing phase‑3 study involving 1,137 patients whose melanomas were surgically removed and who received the vaccine alongside Merck's Keytruda. The companies have not released detailed trial data. Observers note the lack of published results and continue to express caution about mRNA‑based cancer therapies. The announcement has generated mixed reactions among investors and analysts.
How this was covered
- Centrist coverage is the most divided on this story
Why it matters
The trial could point to a new, patient‑specific way to treat melanoma using mRNA technology.
How this story developed
- Aug 19 Moderna shares soar as experimental melanoma vaccine shows promising results
- Aug 19 Moderna’s stock surged after the trial data were released.
- Aug 20 Interim Phase 3 data indicated the vaccine satisfied the primary endpoint of recurrence‑free survival and a key secondary endpoint of distant metastasis‑free survival.
- Aug 24 Moderna’s share price dropped more than 25% after an earlier surge following the trial announcement.
- Aug 28 Companies announced positive topline results from the ongoing phase‑3 trial of the personalized mRNA melanoma vaccine with Keytruda.
Related stories
4 in this thread